Published online before print August 8, 2005, doi: 10.1161/CIRCULATIONAHA.105.556530
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:1016-1023.)
© 2005 American Heart Association, Inc.
Molecular Cardiology |
Native C-Reactive Protein Increases Whereas Modified C-Reactive Protein Reduces Atherosclerosis in Apolipoprotein E–Knockout Mice
From the Department of Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany (S.B.S., C.W., J.G.); Institute of Pathology, University of Erlangen-Nürnberg, Erlangen, Germany (K.A., K.W.); Clinical Biochemistry, University of Greifswald, Greifswald, Germany (A.K., M.N.); and Immtech International, Inc, Vernon Hills, Ill (L.A.P.).
Correspondence to Dr Susanne Schwedler, Department of Medicine, University Hospital Würzburg, Josef-Schneider-Str 2, D-97080 Würzburg, Germany. E-mail Pelleas{at}t-online.de
Received December 19, 2004; de novo received April 18, 2005; accepted May 10, 2005.
Background— C-reactive protein (CRP) may have proatherogenic but also vasoprotective properties. We tested the hypothesis that the configuration of CRP (pentameric, or native [nCRP], versus monomeric, or modified [mCRP]) determines these different characteristics in an in vivo model.
Methods and Results— We investigated the effects of human nCRP and mCRP on the development of atherosclerosis in apolipoprotein E–knockout (ApoE–/–) mice. Treatment with nCRP for 8 weeks (2.5 mg/kg SC weekly) resulted in a 4-fold-higher mean aortic plaque area in 14-week-old female ApoE–/– mice compared with the saline controls. In contrast, mean plaque size was decreased by 
50% in mCRP-treated ApoE–/– mice (2.5 mg/kg SC weekly). Using immunohistochemistry, we report the natural presence of the mCRP antigen in saline controls. mCRP antigen was expressed in smooth muscle cells and extracellularly in the vicinity of the plaques to a similar level in both CRP-treated groups and saline controls. mCRP and ApoB colocalized with macrophages and were equally upregulated in all aortic plaques. Vascular cell adhesion molecule expression was increased, and CD154 and intercellular adhesion molecule showed a trend for higher expression in nCRP-treated compared with mCRP-treated mice. CD154 expression in the vessel wall and plaque size correlated significantly. mCRP-treated ApoE–/– exhibited higher serum levels of the antiinflammatory interleukin-10 compared with the other 2 groups.
Conclusions— Here, we show that mCRP and nCRP have opposite effects on atherosclerosis in ApoE–/– mice. These data may explain in part the conflicting activities previously reported for CRP in models of atherogenesis.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  S. K. Singh, M. V. Suresh, D. C. Prayther, J. P. Moorman, A. E. Rusinol, and A. Agrawal C-Reactive Protein-Bound Enzymatically Modified Low-Density Lipoprotein Does Not Transform Macrophages into Foam Cells J. Immunol., March 15, 2008; 180(6): 4316 - 4322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, D. Liao, U. Bharadwaj, M. Li, Q. Yao, and C. Chen C-Reactive Protein Inhibits Cholesterol Efflux From Human Macrophage-Derived Foam Cells Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 519 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kovacs, P. Tornvall, R. Nilsson, J. Tegner, A. Hamsten, and J. Bjorkegren Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia PNAS, August 21, 2007; 104(34): 13768 - 13773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G O'Neill, D. A Isenberg, and A. Rahman Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? Ann Rheum Dis, August 1, 2007; 66(8): 989 - 991. [Full Text] [PDF]
|
|
|
|
 |
|
 S.-R. Ji, Y. Wu, L. Zhu, L. A. Potempa, F.-L. Sheng, W. Lu, and J. Zhao Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm FASEB J, January 1, 2007; 21(1): 284 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kishimoto A Novel Approach to the Suppression of Atherosclerosis by Fc{gamma} Receptor Blockade Circ. Res., November 24, 2006; 99(11): 1154 - 1155. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Paffen and M. P.M. deMaat C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res, July 1, 2006; 71(1): 30 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, I. Jialal, B. M. Scirica, D. A. Morrow, S. Verma, S. Devaraj, and I. Jialal The Verdict Is Still Out Circulation, May 2, 2006; 113(17): 2128 - 2151. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hermann and F. Ruschitzka Novel anti-inflammatory drugs in hypertension Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-R. Ji, Y. Wu, L. A. Potempa, Y.-H. Liang, and J. Zhao Effect of Modified C-Reactive Protein on Complement Activation: A Possible Complement Regulatory Role of Modified or Monomeric C-Reactive Protein in Atherosclerotic Lesions Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 935 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kishimoto, K. Shioji, and Z. Yuan Fc{gamma}IIB and Cardiovascular Inflammatory Disease Circ. Res., February 17, 2006; 98(3): e26 - e26. [Full Text] [PDF]
|
|
|
|
|
|
E. T.H. Yeh A New Perspective on the Biology of C-Reactive Protein Circ. Res., September 30, 2005; 97(7): 609 - 611. [Full Text] [PDF]
|
|